Eli Lilly and Company: Hepatic Insufficiency trials

The registry lists 12 Hepatic Insufficiency studies with Eli Lilly and Company as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 1 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.RecruitingNCT07401862Phase 1
• A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver ImpairmentRecruitingNCT07165002Phase 1
• Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy ParticipantsCompletedNCT06190691Phase 1Results posted
• A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionCompletedNCT05882032Phase 1Results posted
• A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver FunctionCompletedNCT05440344Phase 1Results posted
• A Study of Tirzepatide in Participants With Impaired Liver FunctionCompletedNCT03940742Phase 1Results posted
• A Study of Abemaciclib in Participants With Varying Degrees of Liver ImpairmentCompletedNCT02387814Phase 1Results posted
• A Pharmacokinetic Study of Baricitinib in Participants With Liver DiseaseCompletedNCT01870388Phase 1Results posted
• A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) ImpairmentCompletedNCT01836185Phase 1Results posted
• A Single Dose Study of LY2605541 in Participants With Liver ImpairmentCompletedNCT01751399Phase 1Results posted
• A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy ParticipantsCompletedNCT06719128Phase 1
• A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionCompletedNCT05916560Phase 1